Taming lupus-a new understanding of pathogenesis is leading to clinical advances

Nature Medicine

Volumn 18, Issue 6, 2012, Pages 871-882

  Liu, Zheng ^a   Davidson, Anne ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BELIMUMAB; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; DRUG MECHANISM; DRUG RESEARCH; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTIVE IMMUNITY; BLOOD-BRAIN BARRIER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SEX CHARACTERISTICS; TOLL-LIKE RECEPTORS;

EID: 84862016703     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2752     Document Type: Review

References (145)

1. Lateef, A. & Petri, M. Biologics in the treatment of systemic lupus erythematosus. Curr. Opin. Rheumatol. 22, 504-509 (2010).
2. Navarra, S.V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
3. Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918-3930 (2011).
4. Morel, L. et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. USA 97, 6670-6675 (2000). (Pubitemid 30412772)
5. Lauwerys, B.R. & Wakeland, E.K. Genetics of lupus nephritis. Lupus 14, 2-12 (2005). (Pubitemid 40216061)
6. Harley, J.B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204-210 (2008). (Pubitemid 351171405)
7. Deng, Y. & Tsao, B.P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 6, 683-692 (2010).
8. Flesher, D.L., Sun, X., Behrens, T.W., Graham, R.R. & Criswell, L.A. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev. Clin. Immunol. 6, 461-479 (2010).
9. Liu, K. et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J. Clin. Invest. 119, 911-923 (2009).
10. Sanchez, E. et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1752-1757 (2011).
11. Cantor, R.M., Lange, K. & Sinsheimer, J.S. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 86, 6-22 (2010).
12. Zhang, J. et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 43, 902-907 (2011).
13. Rieck, M. et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 179, 4704-4710 (2007).
14. Taylor, K.E. et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7, e1001311 (2011).
15. Askanase, A.D. et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J. Rheumatol. 36, 89-95 (2009).
16. Rubtsov, A.V., Rubtsova, K., Kappler, J.W. & Marrack, P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun. Rev. 9, 494-498 (2010).
17. Smith-Bouvier, D.L. et al. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 205, 1099-1108 (2008). (Pubitemid 351679685)
18. Ravichandran, K.S. & Lorenz, U. Engulfment of apoptotic cells: signals for a good meal. Nat. Rev. Immunol. 7, 964-974 (2007). (Pubitemid 350166061)
19. Marínez Valle, F., Balada, E., Ordi-Ros, J. & Vilardell-Tarres, M. DNase 1 and systemic lupus erythematosus. Autoimmun. Rev. 7, 359-363 (2008).
20. Rönnblom, L. & Alm, G.V. The natural interferon-α producing cells in systemic lupus erythematosus. Hum. Immunol. 63, 1181-1193 (2002). (Pubitemid 36025993)
21. Blanco, P., Palucka, A.K., Gill, M., Pascual, V. & Banchereau, J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540-1543 (2001). (Pubitemid 33063928)
22. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003). (Pubitemid 36350866)
23. Bauer, J.W. et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 3, e491 (2006).
24. Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J. & Koutouzov, S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J. Immunol. 174, 2499-2506 (2005). (Pubitemid 40279662)
25. Ramanujam, M. et al. Interferon-α treatment of female (NZW × BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum. 60, 1096-1101 (2009).
26. Nacionales, D.C. et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56, 3770-3783 (2007). (Pubitemid 350100710)
27. Agrawal, H. et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J. Immunol. 183, 6021-6029 (2009).
28. Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006). (Pubitemid 44354221)
29. Thacker, S.G. et al. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J. Immunol. 185, 4457-4469 (2010).
30. Garcia-Romo, G.S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).
31. Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011).
32. Charles, N., Hardwick, D., Daugas, E., Illei, G.G. & Rivera, J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat. Med. 16, 701-707 (2010).
33. Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
34. Boulé, M.W. et al. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (2004). (Pubitemid 38821996)
35. Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569 (2007). (Pubitemid 47525141)
36. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 (2007). (Pubitemid 46605917)
37. Gilliet, M., Cao, W. & Liu, Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8, 594-606 (2008).
38. Rönnblom, L. & Elkon, K.B. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 339-347 (2010).
39. Leadbetter, E.A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002). (Pubitemid 34406754)
40. Berland, R. et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25, 429-440 (2006). (Pubitemid 44376724)
41. Christensen, S.R. & Shlomchik, M.J. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin. Immunol. 19, 11-23 (2007). (Pubitemid 46498753)
42. Christensen, S.R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006). (Pubitemid 44354217)
43. Fossati, L. et al. The Yaa gene-mediated acceleration of murine lupus: Yaa? T cells from non-autoimmune mice collaborate with Yaa+ B cells to produce lupus autoantibodies in vivo. Eur. J. Immunol. 25, 3412-3417 (1995).
44. Barbalat, R., Ewald, S.E., Mouchess, M.L. & Barton, G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214 (2011).
45. Harley, J.B., Harley, I.T., Guthridge, J.M. & James, J.A. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 15, 768-777 (2006).
46. Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501-505 (2007). (Pubitemid 47123520)
47. Ishii, K.J. et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725-729 (2008). (Pubitemid 351220566)
48. Zhang, Z. et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 12, 959-965 (2011).
49. Gall, A. et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36, 120-131 (2012).
50. Goodnow, C.C., Vinuesa, C.G., Randall, K.L., Mackay, F. & Brink, R. Control systems and decision making for antibody production. Nat. Immunol. 11, 681-688 (2010).
51. Arbuckle, M.R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003). (Pubitemid 37255038)
52. Moulton, V.R. & Tsokos, G.C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res. Ther. 13, 207 (2011).
53. Perl, A. et al. T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr. Opin. Rheumatol. 21, 454-464 (2009).
54. Crispín, J.C., Kyttaris, V.C., Terhorst, C. & Tsokos, G.C. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 317-325 (2010).
55. Deng, G.M., Liu, L., Bahjat, F.R., Pine, P.R. & Tsokos, G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 62, 2086-2092 (2010).
56. Ichinose, K., Juang, Y.T., Crispin, J.C., Kis-Toth, K. & Tsokos, G.C. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 63, 523-529 (2011).
57. Bahjat, F.R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433-1444 (2008). (Pubitemid 351705932)
58. Linterman, M.A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561-576 (2009).
59. Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62, 234-244 (2010).
60. Odegard, J.M. et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205, 2873-2886 (2008).
61. Crispín, J.C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761-8766 (2008).
62. Wardemann, H. & Nussenzweig, M.C. B-cell self-tolerance in humans. Adv. Immunol. 95, 83-110 (2007). (Pubitemid 47381589)
63. Liu, Z. & Davidson, A. BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388-394 (2011).
64. Arechiga, A.F. et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 182, 3343-3347 (2009).
65. Menard, L. et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635-3644 (2011).
66. Cappione, A. III et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J. Clin. Invest. 115, 3205-3216 (2005). (Pubitemid 41567585)
67. Gonzalez, S.F. et al. Trafficking of B cell antigen in lymph nodes. Annu. Rev. Immunol. 29, 215-233 (2011).
68. Kranich, J. et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J. Exp. Med. 205, 1293-1302 (2008). (Pubitemid 351831487)
69. Blair, P.A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129-140 (2010).
70. Campbell, D.J. & Koch, M.A. Treg cells: patrolling a dangerous neighborhood. Nat. Med. 17, 929-930 (2011).
71. Kim, H.J. et al. CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc. Natl. Acad. Sci. USA 108, 2010-2015 (2011).
72. Brownlie, R.J. et al. Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J. Exp. Med. 205, 883-895 (2008). (Pubitemid 351549885)
73. Kim, S.J. et al. Increased IL-12 inhibits B cell differentiation to germinal center plasma cells and promotes differentiation to short-lived plasmablasts. J. Exp. Med. 205, 2437-2448 (2008).
74. Herlands, R.A., William, J., Hershberg, U. & Shlomchik, M.J. Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur. J. Immunol. 37, 3339-3351 (2007).
75. Erickson, L.D. et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J. Clin. Invest. 109, 613-620 (2002). (Pubitemid 34204840)
76. Cassese, G. et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726-2732 (2001). (Pubitemid 32898740)
77. Tokoyoda, K., Hauser, A.E., Nakayama, T. & Radbruch, A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol. 10, 193-200 (2010).
78. Merrill, J.T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010).
79. Benson, M.J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659 (2008).
80. Jacobi, A.M. et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201-210 (2010).
81. Looney, R.J., Anolik, J. & Sanz, I. A perspective on B-cell-targeting therapy for SLE. Mod. Rheumatol. 20, 1-10 (2010).
82. Aringer, M. et al. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland-a consensus report. Lupus 21, 386-401 (2012).
83. Hahn, B.H. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann. Rheum. Dis. 70 (suppl. 1), i64-i66 (2011).
84. de Laat, B., Mertens, K. & de Groot, P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat. Clin. Pract. Rheumatol. 4, 192-199 (2008).
85. Lauvsnes, M.B. & Omdal, R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J. Neurol. 259, 622-629 (2012).
86. Faust, T.W. et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl. Acad. Sci. USA 107, 18569-18574 (2010).
87. DeGiorgio, L.A. et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189-1193 (2001).
88. Matus, S. et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J. Exp. Med. 204, 3221-3234 (2007).
89. Kowal, C. et al. Cognition and immunity; antibody impairs memory. Immunity 21, 179-188 (2004). (Pubitemid 39094048)
90. Turnberg, D. & Cook, H.T. Complement and glomerulonephritis: new insights. Curr. Opin. Nephrol. Hypertens. 14, 223-228 (2005). (Pubitemid 40685633)
91. Bergtold, A., Gavhane, A., D'Agati, V., Madaio, M. & Clynes, R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177, 7287-7295 (2006). (Pubitemid 44715098)
92. Anders, H.J. & Schlondorff, D. Toll-like receptors: emerging concepts in kidney disease. Curr. Opin. Nephrol. Hypertens. 16, 177-183 (2007). (Pubitemid 46608524)
93. Manderson, A.P., Botto, M. & Walport, M.J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22, 431-456 (2004). (Pubitemid 38680429)
94. Woodruff, T.M., Nandakumar, K.S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631-1642 (2011).
95. Vielhauer, V., Anders, H.J. & Schlondorff, D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin. Nephrol. 27, 81-97 (2007).
96. Kitching, A.R. & Holdsworth, S.R. The emergence of TH17 cells as effectors of renal injury. J. Am. Soc. Nephrol. 22, 235-238 (2011).
97. Ernandez, T. & Mayadas, T.N. Immunoregulatory role of TNFα in inflammatory kidney diseases. Kidney Int. 76, 262-276 (2009).
98. Bethunaickan, R. et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J. Immunol. 186, 4994-5003 (2011).
99. Hill, G.S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304-316 (2001). (Pubitemid 32063019)
100. Schlondorff, D.O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int. 74, 860-866 (2008).
101. Deelman, L. & Sharma, K. Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr. Opin. Nephrol. Hypertens. 18, 85-90 (2009).
102. Alarcón, G.S. et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 3, e396 (2006).
103. Esdaile, J.M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001). (Pubitemid 32977500)
104. Symmons, D.P. & Gabriel, S.E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 7, 399-408 (2011).
105. Narshi, C.B., Giles, I.P. & Rahman, A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 20, 5-13 (2011).
106. Lopez, L.R. et al. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15, 80-86 (2006). (Pubitemid 43345332)
107. Matsuura, E., Kobayashi, K., Hurley, B.L. & Lopez, L.R. Atherogenic oxidized low-density lipoprotein/β2-glycoprotein I (oxLDL/β2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 15, 478-483 (2006). (Pubitemid 44147097)
108. Skaggs, B.J., Hahn, B.H., Sahakian, L., Grossman, J. & McMahon, M. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. Clin. Immunol. 137, 147-156 (2010).
109. McMahon, M. et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 60, 2428-2437 (2009).
110. Schanberg, L.E. et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 64, 285-296 (2012).
111. Petri, M.A., Kiani, A.N., Post, W., Christopher-Stine, L. & Magder, L.S. Lupus Atherosclerosis Prevention Study (LAPS). Ann. Rheum. Dis. 70, 760-765 (2011).
112. Ceribelli, A., Yao, B., Dominguez-Gutierrez, P.R. & Chan, E.K. Lupus T cells switched on by DNA hypomethylation via microRNA? Arthritis Rheum. 63, 1177-1181 (2011).
113. Pan, Y. & Sawalha, A.H. Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl. Res. 153, 4-10 (2009).
114. Dai, R. & Ahmed, S.A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl. Res. 157, 163-179 (2011).
115. Ceribelli, A. et al. MicroRNAs in systemic rheumatic diseases. Arthritis Res. Ther. 13, 229 (2011).
116. Geuking, M.B. et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34, 794-806 (2011).
117. Illei, G.G. et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 2071-2074 (2011).
118. Choi, E.W. et al. Reversal of serological, immunological and histological dysfunction in systemic lupus erythematosus mice by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 64, 243-253 (2012).
119. Liang, J. et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69, 1423-1429 (2010).
120. Mok, C.C. Biomarkers for lupus nephritis: a critical appraisal. J. Biomed. Biotechnol. 2010, 638413 (2010).
121. Bauer, J.W. et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60, 3098-3107 (2009).
122. Chaussabel, D. et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29, 150-164 (2008). (Pubitemid 351952461)
123. Hinze, C.H. et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 60, 2772-2781 (2009).
124. Rovin, B.H. et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 16, 467-473 (2005). (Pubitemid 41725143)
125. Rubinstein, T. et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49, 960-971 (2010).
126. Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937-941 (2010).
127. Yuan, W., DiMartino, S.J., Redecha, P.B., Ivashkiv, L.B. & Salmon, J.E. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum. 63, 212-218 (2011).
128. Ramanujam, M. & Davidson, A. Targeting of the immune system in systemic lupus erythematosus. Expert Rev. Mol. Med. 10, e2 (2008).
129. Wofsy, D.S., Shropshire, S.M., Hillson, J.L. & Diamond, B. Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data From a multicenter, randomized, double-blind, placebo-controlled phase II/III study. ACR presentation, number 2474 (8 November 2011).
130. Lenert, P.S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010, 986596 (2010).
131. Kyttaris, V.C. & Tsokos, G.C. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr. Opin. Rheumatol. 23, 449-453 (2011).
132. Schiffer, L. et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171, 489-497 (2003). (Pubitemid 36745324)
133. Daikh, D.I. & Wofsy, D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-2916 (2001). (Pubitemid 33117284)
134. Ng, K.P. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259-1262 (2007). (Pubitemid 47309748)
135. Bloom, O. et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc. Natl. Acad. Sci. USA 108, 10255-10259 (2011).
136. Clynes, R., Dumitru, C. & Ravetch, J.V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279, 1052-1054 (1998). (Pubitemid 28113310)
137. Gambaro, G. & Kong, N.C. Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate. J. Nephrol. 23, 244-252 (2010).
138. Nguyen, T.Q. & Goldschmeding, R. Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? Pharm. Res. 25, 2416-2426 (2008).
139. Renner, B. et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 80, 165-173 (2011).
140. Tse, K.C. et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14, 947-952 (2005). (Pubitemid 43088268)
141. McMahon, M., Hahn, B.H. & Skaggs, B.J. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev. Clin. Immunol. 7, 227-241 (2011).
142. Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. published online doi:10.1002/art.34400 (24 January 2012).
143. Liu, Z. & Davidson, A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp. Cell Res. 317, 1270-1277 (2011).
144. Mackay, F. & Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491-502 (2009).
145. Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. published online doi:10.1002/art.34400 (24 January 2012).